Bjørndal M M, Sandmo Wilhelmsen K, Lu T, Jorde R
Institute of Clinical Medicine, University of Tromsø, Norway.
J Endocrinol Invest. 2008 Oct;31(10):856-60. doi: 10.1007/BF03346431.
The causes of subclinical hyperthyroidism have only been reported from clinical studies.
To determine the prevalence and pathological causes of reduced serum TSH levels in subjects recruited from an epidemiological survey.
MATERIAL/SUBJECTS AND METHODS: Serum TSH was measured in 7954 subjects in the 5th Tromsø study. Subjects with serum TSH<0.50 mIU/l, not using T4, without a previous diagnosis of thyroid disease, without serious concomitant disease, and younger than 80 yr, were invited for a re-examination. If low serum TSH was persistent, thyroid scintigraphy was performed.
Among the 4962 subjects that met the inclusion criteria, serum TSH was <0.50 mIU/l in 105 subjects. Twelve subjects had a suppressed serum TSH level (<0.05 mIU/l). Two of these were lost to follow-up, 4 had Graves' disease, 4 had adenoma, and 2 had multinodular goiter. In the 93 subjects with serum TSH 0.05-0.5 mIU/l, 55 were re-examined, of whom 35 had normalized their serum TSH level. In the remaining 20 subjects, 1 had Graves' disease, 6 had adenoma (of which 2 were toxic adenomas), 7 had multinodular goiter, and 6 were considered normal. Among the 521 subjects using T4, 70 (13.4%) had a suppressed serum TSH level.
Most of the subjects with a suppressed serum TSH level will be on T4 medication. Otherwise, if the suppressed serum TSH level is found by chance, this probably represents a clinically important thyroid pathology. Also, in subjects with a persistently low serum TSH level (0.05-0.5 mIU/l) most will have a pathological thyroid scan.
亚临床甲状腺功能亢进症的病因仅来自临床研究报告。
确定在一项流行病学调查中招募的受试者血清促甲状腺激素(TSH)水平降低的患病率及病理原因。
材料/对象与方法:在第五次特罗姆瑟研究中对7954名受试者测定血清TSH。邀请血清TSH<0.50 mIU/l、未使用左甲状腺素(T4)、既往无甲状腺疾病诊断、无严重合并症且年龄小于80岁的受试者进行复查。如果血清TSH持续偏低,则进行甲状腺闪烁扫描。
在符合纳入标准的4962名受试者中,105名受试者血清TSH<0.50 mIU/l。12名受试者血清TSH水平被抑制(<0.05 mIU/l)。其中2名失访,4名患有格雷夫斯病,4名患有腺瘤,2名患有结节性甲状腺肿。在血清TSH为0.05 - 0.5 mIU/l的93名受试者中,55名接受了复查,其中35名血清TSH水平已恢复正常。在其余20名受试者中,1名患有格雷夫斯病,6名患有腺瘤(其中2名为毒性腺瘤),7名患有结节性甲状腺肿,6名被认为正常。在521名使用T4的受试者中,70名(13.4%)血清TSH水平被抑制。
大多数血清TSH水平被抑制的受试者正在接受T4治疗。否则,如果偶然发现血清TSH水平被抑制,这可能代表临床上重要的甲状腺病理情况。此外,血清TSH水平持续偏低(0.05 - 0.5 mIU/l)的受试者大多数甲状腺扫描会显示病理改变。